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Abstract
Background: The hepatitis E virus (HEV) accounts for the hepatitis E infection with a high mortality rate in pregnant women. There-
fore, the design of the novel and effective vaccines seems essential and the DNA vaccine approach could be useful to achieve this
anticipated goal.
Objectives: The aim of this study was the cloning of a secretory form of truncated open reading frame 2 (ORF2) of HEV containing
amino acids (aa) 112 - 607 into the eukaryotic expression pVAX1 Vector and evaluating of the expression of this recombinant protein
in eukaryotic cells.
Methods: The truncated ORF2 gene (aa 112 - 607) was cloned in the pVAX1 plasmid by restriction enzyme digest and confirmed by
digestion and sequencing. Then, the recombinant plasmid was transfected into eukaryotic cells to express the recombinant protein.
The expressed protein in the cell lysate and supernatant was evaluated by immunofluorescence assay (IFA) and western blot assay.
Results: Colony polymerase chain reactions (PCR), restriction enzyme digestion, along with DNA sequencing of the recombinant
plasmid were performed for confirmation of cloning tPA-PADRE-truncated ORF2 gene (aa 112 - 607) into pVAX1 eukaryotic expression
vector. The appearance of the truncated ORF2 protein (56 kDa) in the eukaryotic cells was accepted by the western blot assay, reverse
transcription polymerase chain reaction (RT-PCR) method, as well as IFA.
Conclusions: All outcomes of the present research showed that pVAX1-tPA-PADRE-truncated ORF2 (aa 112 - 607, 56 kDa) recombinant
plasmid was able to express truncated ORF2 from HEV as a potential candidate vaccine.
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1. Background
Hepatitis E virus (HEV) belong to the OrthohepevirusA
species, Orthohepevirus genus, and Hepeviridae family (1).
HEV is transmitted through the path of the fecal-oral and
accounts for critical hepatitis but self-limited infection (2).
Clinical manifestations of HEV infection vary from mod-
erate to severe hepatitis among all group ages (3). High
mortality rate of 25% to 31% have been reported among
pregnant women (4) and 30% to 70% in patients who have
chronic liver diseases (5, 6). In 2016, the world health or-
ganization (WHO) reported that there are approximately
20 million individuals who are infected with HEV, approx-
imately 3.3 million severe cases, and 56600 mortalities an-
nually, which occurs around the world (7).
Hepatitis E virus has been classified into 5 genotypes,
although all the genotypes share 1 serotype. Genotypes 1
and 2 are considered to only infect humans, while geno-
types 3 and 4 are zoonotic; in addition, genotype 5 is re-
stricted to avian infection (8). According to the recent
data, several Asian and African countries, including Iran,
are classified in the high HEV endemicity (9). To date, there
is no exclusive treatment for severe hepatitis E and no ap-
proved licensed vaccine exists against the HEV infection
(10). Thus, based on the aforementioned data, an efficient
vaccine against HEV infection should be developed for pre-
vention of HEV infection. For the time being, no tissue cul-
ture system is available for cultivation of HEV. Therefore,
molecular approaches are only alternative tools for the vac-
cine preparation (11).
Hepatitis E virus genome comprises 3 overlapping
open reading frames (ORF) (12). ORF1 gene is responsible
for enzymatic function and encodes the nonstructural pro-
teins. ORF2 gene involves the synthesis of a viral capsid pro-
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tein (72 kDa) and ORF3 gene encodes a small protein (13.5
kDa), which may have a regulatory function (13). The cap-
sid protein, with 660 amino acids (aa), is highly immun-
odominant and candidates for the HEV vaccine develop-
ment (14). However, it was found that the full-length cap-
sid protein expression is insoluble and less immunologi-
cal reactivity. The construction of a truncated ORF2 protein
(aa 112 to 660), which can be self-assembled into virus-like
particles (VLPs), induces systemic and mucosal immune re-
sponses in experimental animals (15). Thus far, different
truncated forms of the ORF2 protein (aa 112 - 660, aa 112 -
607, aa 458 - 607, as well as aa 368 - 606) have been con-
structed and used for HEV vaccines (16-18).
Since the recombinant vaccines, including DNA vac-
cines, have been developed, in order to improve the vac-
cine potency, several factors such as codon optimization
of the gene, co-administration of different adjuvants, and
use of plasmids encoding a secretory protein type have
been studied. The occurrence of the codon usage is diverse
amongst the numerous organisms. Thus, codon optimiza-
tion can steer towards an extreme expression of the target
gene mimic to the host cell genes (19).
Antigen processing and presentation in cells is an im-
portant key for the activation of both humoral and cell
mediate immunity (20). Since DNA vaccines can be con-
structed for specific cell compartments in antigenic pro-
cessing, vaccination with recombinant DNA can usually ac-
tivate both arms of the immune system. On the other hand,
the existence of a secretary target protein in the cloned
plasmids constructed by fusing target gene to the signal
sequence of human tissue plasminogen activator (tPA) are
found highly immunogenic for both B and T cells, than
the plasmids without a secreted form (21). PADRE peptide,
which is also known as a universal Pan HLA-DR epitope, can
bind to various high-affinity class-2 DR molecules in ma-
jor histocompatibility complexes (MHCs) and can be appli-
cable for humans and mice (22). Based on the aforemen-
tioned data, in this study, a DNA plasmid containing trun-
cated ORF2 (aa 112 - 607) was constructed with tPA-PADRE
genes cassette. The novel chimerical pVAX1-tPA-PADRE-
truncated ORF2 plasmid comprises the secretary signal se-
quence, which derives from tPA, and PADRE sequence, were
fused at the N-terminal of truncated HEV ORF2 gene and
can be used as a candidate HEV vaccine.
2. Objectives
The aim of this study was to construct the recombinant
plasmid pVAX1-tPA-PADRE-truncated ORF2 (aa 112 - 607) as a
DNA vaccine candidate and to evaluate the expression of
cloned, truncated ORF2 of HEV in the pVAX1 vector trans-
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3.2. Construction of ORF2 (aa 112 - 607) from Designed, Opti-
mized pVAX1-tPA-PADRE-Truncated ORF2 (aa 112 - 660) Cassette
of Hepatitis E Virus
The ORF2 gene amino acid sequence (112 - 660) in HEV
genotype 1 from a Pakistani strain (Sar-55) was developed
from the UniProt records (accession number, P33426), de-
signed from the Vector NTI software (version 11.5, Invit-
rogen, USA), optimized using GenScript software, and in-
serted into the pVAX1 plasmid (Invitrogen, USA), as men-
tioned in the previous study (23). To retrieve tPA-PADRE-
truncated ORF2 (aa 112 - 607) gene fragment, 2 restriction
enzyme digestion sites for ScaI were located at a position of
1609 and 1858 at the end of the cassette gene. The arrange-
ment of fragment junctions is shown in Figure 1.
3.3. Sub-Cloning of the Codon-Optimized tPA-PADRE-Truncated
ORF2 Gene Cassette in pVAX1 Eukaryotic Expression Vector
Escherichia coli strain DH5α (Biomedal Life Science,
Spain) containing the pVAX1 eukaryotic expression vector
with tPA-PADRE-truncated ORF2 (aa 112 - 660)-linker in the
previous study (23) was cultured overnight in Luria-Bertani
(LB) broth medium (Merck, Germany), consisting of 50
µg/mL of kanamycin (Sigma-Aldrich, Germany) at a tem-
perature of 37°C. According to the kit’s manufacturer’s in-
structions, the pVAX1 plasmid was extracted using the QIA-
GEN Plasmid Mini Kit (Qiagen, Germany). The purified plas-
mid was digested using the ScaI restriction enzyme (New
England Biolabs, USA) at 37°C for 14 hours. The QIAquick
Gel Extraction Kit (Qiagen, Germany) was used to separate
the linearized, digested pVAX1 plasmid, as well as the tPA-
PADRE-truncated ORF2 (aa 112 - 607) gene from the agarose
gel (1%); afterwards, ligation was performed by T4 DNA lig-
ase (New England Biolabs, USA) at 15°C overnight. The re-
combinant plasmid pVAX1-tPA-PADRE-truncated ORF2 (aa
112 - 607)-linker was assembled (Figure 1B) and transformed
into competent cells of E. coli DH5α strain with 100 mM
of CaCl2 (Merck, Germany) and then chosen on LB agar
medium, consisting of kanamycin (50 µg/mL). Various
colonies were analyzed by the colony PCR and the recombi-
nant plasmids with the accurate restriction patterns were
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Figure 1. The Schematic Model Representing the Development of Recombinant tPA-PADRE-Truncated ORF2 (aa 112 - 607) Gene Cassette
chosen by restriction digestion with NheI and XhoI en-
zymes (New England Biolabs, USA) and then used for DNA
sequencing with T7 Forward and bovine growth hormone
(BGH) reverse primers (by Bioneer, Korea).
The gene fragment encoding tPA-PADRE-truncated
ORF2 (aa 112 - 607), with liker sequence, was PCR am-
plified by using the Q5 High-Fidelity DNA Polymerase
(Qiagen, Germany). The order of forward primer,
which included a Kozak consensus sequence, was
5’-CCAAGCTGGCTAGCTGGAGCCGCCACCATGGATGCA-
3’ and the order of the reverse primer was 5’-
CCCGCTCGAGTTATCACAGTACTGAGTGTGGTGCGAGGAC-3’,
then cloned right into the pVAX1 expression vector using
NheI and XhoI restriction sites. The recombinant plas-
mid was electroporated into E. coli DH5α. The cloning
of the tPA-PADRE-truncated ORF2 (aa 112 - 607) gene into
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the pVAX1 expression vector was confirmed by enzyme
digestions, colony PCR by universal primers (T7, BGH), as
well as DNA sequencing. The verified construct was called
pVAX1-tPA-PADRE-truncated ORF2 (aa 112 - 607) (Figure 1C).
3.4. Expression of the Recombinant pVAX1-tPA-PADRE-Truncated
ORF2 (aa 112 - 607) in Mammalian Cells
To express the recombinant protein in the eukaryotic
cells, CHO and HEK293 cells (National Cell Bank of Iran at
Pasteur Institute) were transfected with the recombinant
plasmid pVAX1-tPA-PADRE-truncated ORF2 (aa 112 - 607) by
PolyFect Transfection Reagent (Qiagen, Germany) confer-
ring to the manufacturer’s guidelines in 6 well culture
plates (Nunc, Denmark). The cells were cultured in Opti-
MEM medium (Gibco-Fisher Scientific, USA) without serum
and antibiotics at 37°C and 5% CO2 to allow gene expres-
sion. To verify mRNA expression of truncated ORF2 gene
(aa 112 - 607), RT-PCR was carried out after 48 hours trans-
fection. In short, the over-all cellular RNA was extracted via
the RNeasy Mini Kit (Qiagen, Germany). In addition, RT-
PCR was then executed by a QIAGEN One Step RT-PCR Kit
(Qiagen, Germany) conferring to the manufacturer’s pro-
tocol by specific primers (upstream primer: F29 (724) 5’-
ATGAAAAGGGGTCTCTGC-3’ and downstream primer: R329
(1053) 5’-ATGCCCAGTACCGCTGGCACG-3’). Then, the RT-PCR
product was electrophoresed on an agarose gel of 2%.
3.5. Confirmation of the Recombinant Protein Expression in Eu-
karyotic Cells
Indirect immunofluorescence assay (IFA) and west-
ern blotting evaluated the expression of the recombinant
truncated ORF2 (aa 112 - 607) protein in the transfected
CHO and HEK293 cells. An IFA using a Fluorescein Isoth-
iocyanate (FITC) -labeled antibody was performed as pre-
viously described (23). The presence of the recombinant
truncated ORF2 (aa 112 - 607, 56 kDa) protein, inside the eu-
karyotic cells, as well as in the supernatants (the secreted
form), was also analyzed by western blotting, according to
the method described previously (24).
4. Results
4.1. Construction of tPA-PADRE-Truncated ORF2 (aa 112 - 607)
Gene Fragment
To construct tPA-PADRE-truncated ORF2 (aa 112 - 607)
gene fragment with linker sequence, digestion with ScaI
restriction enzyme was carried out on a pVAX1-tPA-PADRE-
truncated ORF2 (aa 112 - 660) cassette that had been de-
signed and optimized in the previous study (23). The frag-
ment of tPA-PADRE-truncated ORF2 (aa 112 - 660) was 1948
bp in length; after digestion with ScaI, its length reduced
to 1699 bp (Figure 1A and B). Figure 2 shows agarose gel
electrophoresis of pVAX1-tPA-PADRE-truncated ORF2 (aa 112
- 660) digested with ScaI restriction enzyme. To remove the
linker at a downstream of the gene cassette, PCR amplifi-
cation was performed on pVAX1-tPA-PADRE-truncated ORF2
(aa 112 - 607)-linker cassette and PCR product with 1624 bp
in length was produced. This fragment was called pVAX1-
tPA-PADRE-truncated ORF2 (aa 112 - 607) (Figure 1C).
Figure 2. Agarose Gel Electrophoresis of pVAX1-tPA-PADRE-Truncated ORF2 (aa 112 -
660) Single Digestion with ScaI
Lane M, 1 kb DNA marker. Lane 1, pVAX1-tPA-PADRE-truncated ORF2 (aa 112 - 660) di-
gested with ScaI and production of 2 expected fragments 4602 bp and 249 bp; Lane
2 and 3, pVAX1-tPA-PADRE-truncated ORF2 (aa 112 - 607) digested ScaI and production
of 4602 bp linear plasmid.
4.2. Subcloning Results of tPA-PADRE-Truncated ORF2 (aa 112 -
607) Gene Fragment in the pVAX1 Eukaryotic Plasmid
Subcloning of pVAX1 containing tPA-PADRE-truncated
ORF2 (aa 112 - 607) gene fragment was approved by colony
PCR and restriction enzyme digestion with NheI and XhoI
enzymes (Figure 3). DNA sequencing with universal
primers (T7, BGH) confirmed the cloned gene fragment.
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Figure 3. Subcloning of Optimized tPA-PADRE-Truncated ORF2 (aa 112 - 607) Gene Cassette in the pVAX1 Eukaryotic Plasmid
Lane M1 , DNA marker (1 kb); Lane M2 , DNA marker (100 bp); Lane 1,2: PCR product of tPA-PADRE-truncated ORF2 (aa 112 - 607) by specific primers; Lane 3, pVAX1 plasmid with
digestion by NheI and XhoI; Lane 4, pVAX1 plasmid with digestion by NheI; Lane 5, pVAX1-tPA-PADRE-truncated ORF2 (aa 112 - 607) without digestion; Lane 6, pVAX1-tPA-PADRE-
truncated ORF2 (aa 112 - 607) digested with xho; Lane 7, pVAX1-tPA-PADRE-truncated ORF2 (aa 112 - 607) digested with NheI and XhoI; Lane 8 and 9, PCR product of pVAX1-tPA-
PADRE-truncated ORF2 (aa 112 - 607) plus linker by T7 and BGH primers.
4.3. Expression and Confirmation of the Recombinant tPA-
PADRE-Truncated ORF2 (aa 112 - 607, 56 kDa) Protein in Mam-
malian Cells
The expression of the recombinant tPA-PADRE-
truncated ORF2 (aa 112 - 607, 56 kDa) protein was con-
firmed in the eukaryotic cells (HEK293 and CHO cells) by
RT-PCR assay. The PCR product was sized to be 329 bp. The
expression of tPA-PADRE-truncated ORF2 (aa 112 - 607, 56
kDa) protein in CHO cells was confirmed by IFA using anti
HEV polyclonal antibody (Figure 4). Western blot analysis
detected the expression of tPA-PADRE-truncated ORF2 (aa
112 - 607, 56 kDa) protein in both the supernatant and
lysates collected from the transfected HEK293 cells (Figure
5).
5. Discussion
Although most HEV infections are asymptomatic,
some can cause acute hepatitis with several clinical
manifestations including glomerulonephritis, thrombocy-
topenia, and neurological disorder (25). In addition, HEV
infection can be severe in pregnant women with a high
mortality and morbidity rate, especially in developing
countries leading to fulminant hepatic failure, and in
patients with a super-infection (1). Chronic HEV infections
may also occur in immunocompromised patients (2).
Due to lack of proper treatments for HEV infections, the
existence of active immunization remains only alternative
for the prevention of HEV infections. Several attempts have
been made to develop a HEV vaccine (26). Since there is no
efficient tissue culture system for cultivation of HEV, the re-
combinant DNA technology is the only approach in devel-
oping an HEV vaccine (27). To achieve this, DNA vaccines
have been discovered to have several advantages includ-
ing cost-effective, stability, and higher immunogenicity of
a target antigen (28). Numerous reports revealed that the
effectiveness of immune responses have been stimulated
by DNA vaccines (29). The DNA-based vaccine was found to
stimulate the CD4+ T helper cell immune responses, follow-
ing the activated CD4+ T helper cells outcome in the pro-
duction of CD8+ T cell immune responses, as well as the
memory T cell responses (30).
Some studies show that the HEV ORF2-induced anti-
body exists for long periods in animals as well as humans
and shows a cross-reaction among different HEV geno-
types. It can also neutralize HEV in vitro. Due to its effec-
tive immunogenicity, the HEV ORF2 protein has been used
as an antigen for all vaccine research studies until now
(10). DNA vaccine studies have revealed that the codon op-
timization could enhance the expression of recombinant
proteins (31). The present study displays that the codon op-
timization for expressing the recombinant truncated ORF2
gene is effective in eukaryotic cells, which is consistent
with the previous report (23).
Several studies demonstrate that the expression of dif-
ferent target genes can be highly efficiently achieved by the
Jundishapur J Microbiol. 2017; 10(11):e13543. 5
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Figure 4. Expression Analysis of HEV Truncated ORF2 Protein (aa 112 - 607) in CHO Cells by Immunofluorescence Assay (IFA)
Detection of HEV truncated ORF2 protein (aa 112 - 607, 56 kDa) in CHO cells (A1 and A2) transfected with pVAX1-tPA-PADRE-truncated ORF2 (aa 112 - 607) recombinant plasmid by
IFA. B1 and B2, CHO cells transfected cells with pVAX1 plasmid (negative control). DAPI was used to stain the cell nuclei (A1 and B1).
pVAX1 vector. Using pVAX1 for designing and constructing
the target gene has several advantages such as stability and
cost-effectiveness, especially for developing countries (32).
To enhance the protein yield, adding of Kozak sequence
to the upstream of the initiation codon can increase the
protein expression level. As a result, in the present study,
the Kozak sequence was joined with truncated ORF2 (aa
112 - 607, 56 kDa) gene sequence at N-terminal exactly be-
fore the start codon of the gene. The study conducted by
Farshadpour et al. shows the proper expression of trun-
cated ORF2 (aa 112 - 660, 63 kDa) in HEK293 and CHO cells
using the Kozak sequence (23). The presence of the sig-
nal sequence of tPA in a target gene leads to construct a
secretary form of the protein, which makes it better to
present to both T and B cells (21). In other words, the se-
cretion of a protein will boost the antigen presentation via
MHC class II, which result in enhancing the activation of
antigen-specific CD4+ T-cells. Thus, in the present study,
the secretory tissue plasminogen activator (tPA) sequence
was used in DNA vaccine construction. In addition, the ex-
istence of PADRE sequence improves the presentation of
a target peptide via MHC class II for CTL responses. Some
studies revealed that PADRE peptide is capable of attaching
to the alternates of human MHC class II molecules DR and
stimulate helper-mediated immune responses in human
species, as well as mice. It can also enhance the potency
of vaccines in preclinical models (33, 34). Therefore, in the
present study, the sequence of tPA and PADRE were added
respectively after the Kozak sequence to the N-terminal se-
quence of truncated ORF2 (aa 112 - 607) gene.
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Figure 5. Expression Analysis of HEV Truncated ORF2 Protein (aa 112 - 607, 56 kDa) in
Transfected HEK293 Cells by Western Blotting
Lane M, pre-stained protein ladder; Lane 1, HEK293 cells transfected with pVAX1 (as
negative control); Lane 2, detection of truncated ORF2 protein (aa 112 - 607) in the
supernatant of HEK293 cells transfected with pVAX1-tPA-PADRE-truncated ORF2 (aa
112 - 607) recombinant plasmid; Lane 3, detection of truncated ORF2 protein (aa 112 -
607) in cell lysate of HEK293 cells transfected with pVAX1-tPA-PADRE-truncated ORF2
(aa 112 - 607) recombinant plasmid. A protein band about 56 kDa corresponding to
tPA-PADRE-truncated ORF2 (aa 112 - 607) recombinant protein is detected.
6. Conclusion
In conclusion, this study showed that the encoded
truncated form of HEV capsid protein (ORF2) (aa 112 - 607,
56 kDa) was efficaciously expressed in eukaryotic cells; al-
though, the immunogenicity of pVAX1 containing trun-
cated ORF2 (aa 112 - 607) requires to assess in vivo immuno-
logically and cell mediated immune response.
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